Wang Chung-Jen, Cheng Shih-Lung, Kuo Sow-Hsong
Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22056, Taiwan.
Department of Chemical Engineering and Materials Science, Yuab Ze University, Taoyuan City 32003, Taiwan.
Life (Basel). 2022 Jan 20;12(2):153. doi: 10.3390/life12020153.
Management of patients with asthma during the coronavirus disease 2019 (COVID-19) pandemic is a concern, especially since asthma predisposes patients to respiratory problems. Interestingly, asthma characterized by type 2 inflammation, also known as T-helper type 2-high endotype, displays a cellular and molecular profile that may confer protective effects against COVID-19. The results of experimental and clinical studies have established the actions of immunoglobulin E (IgE) in inducing airway hyperreactivity and weakening an interferon-mediated antiviral response following respiratory viral infection. Robust evidence supports the beneficial effect of the anti-IgE biologic treatment omalizumab on reducing respiratory virus-induced asthma exacerbations and reducing the frequency, duration, and severity of respiratory viral illness in patients with asthma. Indeed, accumulating reports of patients with severe asthma treated with omalizumab during the pandemic have reassuringly shown that continuing omalizumab treatment during COVID-19 is safe, and in fact may help prevent the severe course of COVID-19. Accordingly, guidance issued by the Global Initiative for Asthma recommends that all patients with asthma continue taking their prescribed asthma medications, including biologic therapy, during the COVID-19 pandemic. The impact of biologic treatments on patients with asthma and COVID-19 will be better understood as more evidence emerges.
在2019冠状病毒病（COVID-19）大流行期间，哮喘患者的管理备受关注，尤其是因为哮喘使患者易患呼吸道疾病。有趣的是，以2型炎症为特征的哮喘，也称为2型辅助性T细胞高内型，表现出一种细胞和分子特征，可能对COVID-19具有保护作用。实验和临床研究结果已证实免疫球蛋白E（IgE）在呼吸道病毒感染后诱导气道高反应性以及削弱干扰素介导的抗病毒反应方面的作用。有力证据支持抗IgE生物制剂奥马珠单抗在减少呼吸道病毒诱发的哮喘发作以及降低哮喘患者呼吸道病毒疾病的频率、持续时间和严重程度方面的有益作用。事实上，大流行期间接受奥马珠单抗治疗的重度哮喘患者的越来越多的报告令人放心地表明，在COVID-19期间继续使用奥马珠单抗治疗是安全的，而且实际上可能有助于预防COVID-19的严重病程。因此，全球哮喘防治创议发布的指南建议，在COVID-19大流行期间，所有哮喘患者继续服用其规定的哮喘药物，包括生物疗法。随着更多证据的出现，生物治疗对哮喘和COVID-19患者的影响将得到更好的理解。
